BIOMEDICA CROBIOMEDICA CRO
  • +38 (068) 150 70 04
  • office@biomedica-cro.com
  • Biospecimens
    • Tissue Samples
    • Blood samples
    • Other Biofluids
    • Inventory
  • Disease Areas
  • Ethics
  • Blog
  • About us
  • Contacts
  • ENEN
    • UAUA
Search
SEND REQUEST
  • Biospecimens
    • Tissue Samples
    • Blood samples
    • Other Biofluids
    • Inventory
  • Disease Areas
  • Ethics
  • Blog
  • About us
  • Contacts
  • Home
  • Blog
  • Prospective collection of blood for novel Liquid Biopsy test development

Prospective collection of blood for novel Liquid Biopsy test development

Prospective collection of blood for novel Liquid Biopsy test development

28.06.2022
Prospective collection of samples for your research by BIOMEDICA CRO. Our main area is oncology – Breast, CRC, Ovarian, Prostate, Lung, and Stomach cancer patients can become donors for your research.
admin2024-05-29T14:40:40+00:00

Prospective collection of biospecimens for Automated Liquid Biopsy test development – a short review of the latest investigations by BIOMEDICA CRO

A novel, Automated Liquid Biopsy test in development by researchers at the Johns Hopkins Kimmel Cancer Center can accurately detect the presence of cancer DNA in the blood of patients with metastatic Breast cancer within five hours.
The test, called the Liquid Biopsy for Breast Cancer Methylation (LBx-BCM), is compatible with a commercially available molecular testing platform called GeneXpert® and can detect methylation, a type of chemical tag, in one or more of nine genes altered in Breast cancers in 4.5 hours.

For this study, scientists used prospective collection of blood from donors with metastatic Breast carcinoma.
They examined cumulative methylation of the 9 genes in 20 serum samples from patients with metastatic Breast cancer and 20 from people without oncology. A second set of samples from 40 people with metastatic Breast cancer, 17 with benign Breast disease and nine without cancer, was analyzed. In both sets, LBx-BCM detected two- to 200-fold more methylated DNA in plasma samples from those with Breast cancer than in normal or benign samples.

“Further prospective clinical trials will evaluate LBx-BCM’s detection sensitivity and its ability to monitor therapeutic response during treatment for advanced Breast cancer,” Sukumar and colleagues wrote.

Please find more information in the AACR journal, research article, “Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer”.

Prospective collection of samples for your research by BIOMEDICA CRO

BIOMEDICA CRO provides both prospective and retrospective collections of the numerous human biospecimen types  and associated clinical data since 2017.
Our main area is oncology – Breast, CRC, Ovarian, Prostate, Lung, and Stomach cancer patients can become donors for your research. Besides oncology, we have 50+ contracted clinical sites in a broad range of disease areas.

Due to our business model and direct way of communication with Primary Investigators you will get the highest quality of human biospecimen and insurance that all project details are followed.

For instance, we can provide next types of blood samples:

  • Whole blood;
  • Serum;
  • Buffy coat;
  • PBMCs;
  • Red sells, etc.

BIOMEDICA CRO operates within the strictest ethical guidelines.
It means that all clinical materials are exclusively obtained after approval of the Institutional Review Board or the Independent Ethical Committee (IRB/IEC) as well as all donors are mandatory consented and signed the Individual Consent Form.

Please email us to start our collaboration: office@biomedica-cro.com / LinkedIn.

Feel free to place a request for human biospecimens.

Share this post

Facebook Twitter LinkedIn
All publications
Cancer gene mutations research and contribution of human biospecimens providers
TILs therapy and how BIOMEDICA CRO may help to move science forward
  • Biospecimens
  • Disease Areas
  • Ethics
  • Blog
  • About us
  • Contacts

Privacy Policy | Terms of use

Linkedin

Site development mamontova design

BIOMEDICA CRO
© 2021 | All rights reserved

View the Inventory

Click on the button "Download the inventory" to review the list of ready-to-ship biospecimens.

Download the Inventory

Iryna Iurkova

Business Development Director

Ms. Iurkova is experienced in brand promotion, business development, marketing communications, and public relations. Prior to becoming Business Development Director for BIOMEDICA CRO, Iryna worked at Deloitte, Bayer, and AB InBev. She has a Master’s Degree in International Business Management. For the last seven years, Iryna has successfully worked in the field of human biospecimens, managing numerous complex projects.

Serhii Samsoniuk

Chief Executive Officer

Mr. Samsoniuk is a pharmaceutical expert with over 15 years of industry experience. Over the course of his career, he has held key leadership roles at both international and local companies, such as GlaxoSmithKline, B.Braun, and Sona Exim, overseeing strategic marketing, sales, and key account management. Before joining BIOMEDICA CRO team, he led business development efforts in the CCA+ region at Farmak, driven by a commitment to professional ethics and strategic partnership.

Anton Zubov - MD, BIOMEDICA CRO Co-Founder, Board Member

Anton Zubov

MD, BIOMEDICA CRO Co-Founder,
Board Member

Dr. Zubov has over 21 years of experience in the international pharmaceutical markets. He has held numerous leading positions in marketing, management and sales at Schering AG and Bayer Pharmaceuticals. He has made a career internationally with positions in Ukraine, Germany and Central Asia. In 2017, together with Dr. Kupnovitsky, he founded BIOMEDICA CRO and during the first years was its CINO. Dr. Zubov is currently a Marketing & Sales Director of the CIS Region in Farmak and Board Member of BIOMEDICA CRO Supervisory Board.

have any questions?

Send request

Fill out the form and we will contact you shortly

    Name

    E-mail

    Your message


    have any questions?

    Send request

    Please send us a message and we’ll be back to you shortly

      Name

      Company name

      E-mail

      Your message

      Ostap Kupnovitsky - PhD, MD, MBA, BIOMEDICA CRO Co-Founder, Chairman of the Supervisory Board

      Ostap Kupnovitsky

      PhD, MD, MBA,
      BIOMEDICA CRO Co-Founder,
      Chairman of the Supervisory Board

      Dr. Kupnovitsky has a vast experience in the pharmaceutical market. He was the Regional Director of Organon and Serono in Ukraine. In 2003, he became a Co-Founder and Director of Sona-Pharm, the firm that started its activity in Ukraine and has flourished into an international marketing company with its representatives throughout the CIS region. Since 2017, when BIOMEDICA CRO was founded, he has been a distinguished Chairman of its Supervisory Board.